Financial Comparison: Carisma Therapeutics (CARM) and The Competition

Posted by on Jun 7th, 2023

Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 372 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Carisma Therapeutics to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Carisma Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics 0 0 3 0 3.00
Carisma Therapeutics Competitors 512 1553 4249 40 2.60

Carisma Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 24.14%. As a group, “Biotechnology” companies have a potential upside of 88.14%. Given Carisma Therapeutics’ rivals higher possible upside, analysts clearly believe Carisma Therapeutics has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

16.5% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 27.4% of shares of all “Biotechnology” companies are owned by institutional investors. 17.0% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 24.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Carisma Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Carisma Therapeutics’ rivals have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Carisma Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Carisma Therapeutics N/A -9.52% -7.29%
Carisma Therapeutics Competitors -994.13% -298.75% -21.34%

Valuation & Earnings

This table compares Carisma Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Carisma Therapeutics $40.00 million -$19.88 million -1.84
Carisma Therapeutics Competitors $140.54 million -$6.47 million -46.57

Carisma Therapeutics’ rivals have higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Carisma Therapeutics rivals beat Carisma Therapeutics on 7 of the 13 factors compared.

About Carisma Therapeutics

(Get Rating)

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.